How much can change in a year?
In the past 12 months, the RLT industry hasn’t just moved forward, it’s gone nuclear!
Over the past month alone, the sector has surged ahead through deal‑making, rapid late‑stage pipeline progression, and the expansion of commercial‑scale production.
This year’s TRP Summit is tightly aligned to the latest industry news, pairing the exact developments shaping the market with the people behind them.
DISCOVERY & PRECLINICAL
Pioneering safety, toxicology, predictive modelling, AI and non-clinical considerations
Molecular Partners advances Radio-DARPin® platform for targeted radiopharmaceuticals
(Martin Steegmaier, CSO,
Molecular Partners AG)
Affibody expands engineered scaffold proteins for precise targeting and improved
tumour penetration
(Fredrik Frejd, CSO, Affibody AB)
ARTBIO progresses Alpha Radioligand Therapy pipeline with multiple
clinical-stage candidates
(Tanja Aravak, Director – Program Management, Alpha Radioligand Therapy, ARTBIO)
Tagworks demonstrates click-chemistry platform enabling novel targeting of previously intractable cancers
(Marc Robillard, CSO & Founder, Tagworks Pharmaceuticals BV)
TRANSLATIONAL & CLINICAL
Translating innovation into first-in human studies and clinical impact
Ratio Therapeutics expands clinical theranostic pipeline across multiple solid tumour indications
(John Babich, President & CSO, Ratio Therapeutics)
Telix continues leadership in patient selection, imaging biomarkers and dosimetry optimisation
(Anil Lalwani, Vice President, Clinical Development, Telix Pharmaceuticals)
Orano Med advances targeted alpha therapy clinical development across
expanding indications
(Frédéric Desdouits, CEO, Orano Med)
Novartis clinical updates shaping the future of radioligand therapy development
(Shefali Kakkar, Global Head of Radioligand Therapy Development, Novartis)
CMC & SUPPLY
Building resilient supply chains, and scalable compliant manufacturing
Bicycle Therapeutics secures long-term Pb-212 supply agreement with SpectronRx – 400 tonnes over 5 years
(Michael Method, Chief Medical Officer, Bicycle Therapeutics)
IAEA updates transport and logistics guidance as radiopharmaceutical supply chains become increasingly complex
(Christopher Jones, Office for Nuclear Regulation / IAEA Transport Safety Standards Committee)
AstraZeneca commits major investment into radioconjugate manufacturing expansion
(Mark Fielding, Director – CMC, Regulatory Affairs & Radiopharmaceuticals, AstraZeneca)
Regulators increase emphasis on comparability, process validation and manufacturing readiness
(Gary Inwards, Senior Pharmaceutical Assesor, MHRA)
Europe's Most Comprehensive End-to-End Forum Dedicated
to Targeted Radiopharmaceutical Development
- 50+ World-Class Speakers from Across the TRP Ecosystem
- 20+ Hours of Curated Networking, Including Meet & Match Partnering
- 15+ Exclusive Clinical Readouts & Real-World Case Studies
- Brand-New Interactive Workshops & Seminars
- Europe's Strongest Regulatory Faculty (MHRA, Swissmedic, IAEA & ONR)
- The Great Isotope Debate
Explore the Agenda
Discover the scientific, clinical and commercial strategies that will become your blueprint for accelerating targeted radiopharmaceuticals from discovery to patients.
Partner With Us
Showcase your technologies and services to 200+ senior decision-makers actively seeking CROs, CDMOs, isotope suppliers, radiopharmacies, dosimetry providers and specialist partners to advance the next generation of radiopharmaceuticals.
Join Europe's TRP Leaders:
Be part of Europe's most comprehensive targeted radiopharmaceuticals forum, uniting pharma, biotech, regulators, clinical centres, investors and solution providers to shape the future of radioligand therapy.